[HTML][HTML] Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease
Trimetazidine is a cytoprotective drug whose cardiovascular effectiveness, especially in
patients with stable ischemic heart disease, has been the source of much controversy in
recent years; some have gone so far as to treat the medication as a 'placebo drug'whose
new side effects, such as Parkinsonian symptoms, outweigh its benefits. This article is an
attempt to present the recent key studies, including meta-analyses, on the use of
trimetazidine in chronic heart failure, also in patients with diabetes mellitus and arrhythmia …
patients with stable ischemic heart disease, has been the source of much controversy in
recent years; some have gone so far as to treat the medication as a 'placebo drug'whose
new side effects, such as Parkinsonian symptoms, outweigh its benefits. This article is an
attempt to present the recent key studies, including meta-analyses, on the use of
trimetazidine in chronic heart failure, also in patients with diabetes mellitus and arrhythmia …
Abstract
Trimetazidine is a cytoprotective drug whose cardiovascular effectiveness, especially in patients with stable ischemic heart disease, has been the source of much controversy in recent years; some have gone so far as to treat the medication as a ‘placebo drug’ whose new side effects, such as Parkinsonian symptoms, outweigh its benefits. This article is an attempt to present the recent key studies, including meta-analyses, on the use of trimetazidine in chronic heart failure, also in patients with diabetes mellitus and arrhythmia, as well as in peripheral artery disease. This paper also includes the most recent European Society of Cardiology guidelines, including those of 2013, on the use of trimetazidine in cardiovascular disease.
Springer
